Bristol Myers Squibb deploys advanced NVIDIA AI factory for drug discovery

Bristol Myers Squibb (BMS) is significantly expanding its AI capabilities by deploying a second NVIDIA DGX SuperPOD, built on eight DGX Vera Rubin NVL72 systems. This new infrastructure aims to provide all scientists within the company access to powerful AI tools, including the NVIDIA BioNeMo Agent Toolkit, for accelerating drug discovery and development. The company expects this upgrade to deliver up to 10x the performance per megawatt compared to its previous systems, enabling faster predictions, model training, and agentic workflows across the entire drug discovery pipeline. AI

IMPACT Accelerates drug discovery cycles and expands research capabilities by providing scalable AI compute resources.

RANK_REASON Significant infrastructure deployment by a major pharmaceutical company using advanced AI hardware. [lever_c_demoted from significant: ic=1 ai=0.7]

Read on NVIDIA Blog →

• Bristol-Myers Squibb
• Chelmodeyevskiy Maydan
• DGX SuperPOD
• DGX Vera Rubin NVL72
• Erin Davis
• NVIDIA
• NVIDIA BioNeMo Agent Toolkit
• Payal Sheth
• Vera Rubin

• infra
• product

AI-generated summary · Google Gemini · from 1 sources. How we write summaries →